Skip to main content
. 2021 Dec 26;22(7):e452–e458. doi: 10.1016/j.clml.2021.12.011

Figure 3.

Figure 3

Overall survival, hematologic malignancy (HM) subgroup analysis. (A) (top), compares the survival probability of the HM cohort who were on active treatment at the time of COVID-19 infection (red), compared to those who were not on active treatment (blue). (B) (bottom), compares the survival probability of the HM cohort who were in complete remission (CR) (red) compared to the HM patients not in CR (blue). Neither P value reaches statistical significance for a difference between these cohorts. For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.